## SRPT: Sarepta Therapeutics, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.7% below STRENGTH zone (3.0-6.0%); PEG 159.25 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.0% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($18.32)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Neutral (Bullish: 0, Bearish: 1)

**1. Assessing Sarepta Therapeutics (SRPT) Valuation After a Recent Share Price Rebound**
- Source: Simply Wall Street | 20251217T090912 | Neutral | Relevance: 100%
- Sarepta Therapeutics (SRPT) has seen a recent share price rebound of 18.61% over the last month, despite a challenging year where the stock is still down significantly. The company's valuation is complex, with a narrative model suggesting it's 9% overvalued, while its 1x price-to-sales ratio appears cheap compared to biotech peers. Analysts have a wide range of price targets for SRPT, highlighting disagreement on its future earnings growth and profitability.

**2. Sarepta Therapeutics (NASDAQ:SRPT) COO Ian Michael Estepan Sells 13,187 Shares**
- Source: MarketBeat | 20251219T020903 | Neutral | Relevance: 100%
- Sarepta Therapeutics (NASDAQ:SRPT) COO Ian Michael Estepan sold 13,187 shares of the company's stock on December 16th at an average price of $22.31, totaling $294,201.97. This transaction reduced his stake by 6.39% to 193,300 shares. Despite missing EPS estimates, Sarepta's recent quarterly revenue of $399.36 million exceeded analyst expectations, though it was down 14.5% year-over-year.

**3. Will FDA Liver Warning and Newborn Screening Expansion Change Sarepta Therapeutics' (SRPT) Riskâ€‘Reward Narrative?**
- Source: Simply Wall Street | 20251218T130925 | Neutral | Relevance: 100%
- Sarepta Therapeutics faces a new FDA boxed warning for acute liver injury with its gene therapy ELEVIDYS, restricting its use. Concurrently, the expansion of newborn screening for Duchenne muscular dystrophy could broaden the patient pool for Sarepta's treatments. These developments create a mixed risk-reward outlook, with heightened safety concerns balancing the potential for earlier diagnosis and increased demand.

**4. Sarepta Therapeutics, Inc. (SRPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation**
- Source: CBS 17 | 20251217T160925 | Bearish | Relevance: 100%
- Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Sarepta Therapeutics, Inc. (NASDAQ:SRPT) following a significant stock price drop. The investigation stems from Sarepta's disclosure on November 3, 2025, that its late-stage ESSENCE trial for two Duchenne muscular dystrophy gene therapies failed to meet its primary endpoint's statistical significance. The firm is encouraging stockholders who purchased Sarepta securities to contact them to assist with the investigation.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Wedbush | $32 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Wedbush | init | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 4 ($0.39M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 106.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Tudor Investment Cor: 65.7% (+135261.8%)
- Blackrock Inc.: 12.6% (+8.9%)
- Vanguard Group Inc: 10.3% (+18.1%)
- State Street Corpora: 5.1% (+13.0%)
- Erste Asset Manageme: 2.6% (+65.7%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-3.0% 5d) with bearish MACD, trend may be turning.
2. Valuation stretched: PEG 159.2x requires aggressive growth execution.
3. High short interest (21.6%, 3.4 days to cover): squeeze risk or crowded bearish bet.
4. Long-term trend broken: trading 34.4% below SMA200.
5. Falling knife pattern: rapid decline without stabilization, catch risk elevated.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 159.25 signals overvaluation risk, limited margin of safety. Balance sheet: strong liquidity (3.0x). Revenue declining -25% YoY, concerning. Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $2.2B |
| Beta | 0.53 |
| 52W Range | $10.42 - $129.84 |
| Short Interest | 21.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 159.25 |
| Forward P/E | 7.3 |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 deteriorating from 0.4% to -2.7% (-3.0% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.7pp (needs >3.0% for momentum thesis). Below SMA200 (0.66x), long-term trend not supportive. RSI neutral at 51. OFD pattern: +MUH (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.68% (CS: 16) | Weak |
| RSI_14 | 51.1 | Neutral |
| MACD Histogram | -0.07 | Bearish |
| vs SMA20 | 0.999x | Below |
| vs SMA50 | 1.012x | Above |
| vs SMA200 | 0.656x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $21.04
- **Stop Loss:** $18.32 (12.9% risk)
- **Target:** $23.76 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 441
- **Position Value:** $9,278.64
- **Portfolio %:** 9.28%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-02-25 (Est: $-0.71)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.37 | $-0.13 | +65.0% |
| 2025Q2 | $1.16 | $2.02 | +73.9% |
| 2025Q1 | $-0.65 | $-3.42 | -426.6% |
| 2024Q4 | $2.06 | $1.90 | -7.8% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*